“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Coherus BioSciences


Coherus BioSciences Product


  • Cimerli®

    • Generic: ranibizumab‑eqrn

    • Indication: biosimilar to Lucentis® for age-related macular degeneration and related eye conditions

L

  • Loqtorzi®

    • Generic: toripalimab‑tpzi

    • Indication: anti‑PD‑1 immunotherapy approved for recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination with chemotherapy or as monotherapy

U

  • Udenyca® (previously marketed; divested 2024)

    • Generic: pegfilgrastim‑cbqv

    • Indication: biosimilar to Neulasta®, used to reduce the incidence of infection (febrile neutropenia) in patients undergoing myelosuppressive anti-cancer treatment

Y

  • Yusimry®

    • Generic: adalimumab‑aqvh

    • Indication: biosimilar to Humira® for various autoimmune inflammatory diseases (e.g., rheumatoid arthritis, psoriasis)




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)